NO317194B1 - Fremgangsmate for fremstilling av eprosartan - Google Patents
Fremgangsmate for fremstilling av eprosartan Download PDFInfo
- Publication number
- NO317194B1 NO317194B1 NO19993913A NO993913A NO317194B1 NO 317194 B1 NO317194 B1 NO 317194B1 NO 19993913 A NO19993913 A NO 19993913A NO 993913 A NO993913 A NO 993913A NO 317194 B1 NO317194 B1 NO 317194B1
- Authority
- NO
- Norway
- Prior art keywords
- acid
- compound
- formula
- butyl
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title claims description 13
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 title claims description 12
- 239000002080 C09CA02 - Eprosartan Substances 0.000 title claims description 10
- 229960004563 eprosartan Drugs 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- QHDUBNMGSDGCKZ-UHFFFAOYSA-N piperidin-1-ium;propanoate Chemical group CCC(O)=O.C1CCNCC1 QHDUBNMGSDGCKZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- QLMGJDCOKQGJKF-UHFFFAOYSA-N 4-[(2-butyl-5-formylimidazol-1-yl)methyl]benzoic acid Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C(O)=O)C=C1 QLMGJDCOKQGJKF-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- XRHARLSZTAQDFH-UHFFFAOYSA-N CCC(C(O)=O)(C(O)=O)CC1=CC=CS1 Chemical compound CCC(C(O)=O)(C(O)=O)CC1=CC=CS1 XRHARLSZTAQDFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- -1 eprosartan Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- ZEHWMEOIILLKJJ-XSFVSMFZSA-N 4-[[2-butyl-5-[(e)-3-ethoxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(=O)OCC)/CC1=CC=CS1 ZEHWMEOIILLKJJ-XSFVSMFZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- AHKJGIUKIBGOKH-UHFFFAOYSA-N morpholine;piperidine Chemical compound C1CCNCC1.C1COCCN1 AHKJGIUKIBGOKH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- DZWPLVNHROYBEH-UHFFFAOYSA-N piperidin-1-ium;propanoate;propanoic acid Chemical compound CCC(O)=O.CCC([O-])=O.C1CC[NH2+]CC1 DZWPLVNHROYBEH-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3819597P | 1997-02-14 | 1997-02-14 | |
| PCT/US1998/002412 WO1998035963A1 (en) | 1997-02-14 | 1998-02-13 | Process for preparing eprosartan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993913D0 NO993913D0 (no) | 1999-08-13 |
| NO993913L NO993913L (no) | 1999-08-13 |
| NO317194B1 true NO317194B1 (no) | 2004-09-13 |
Family
ID=21898583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993913A NO317194B1 (no) | 1997-02-14 | 1999-08-13 | Fremgangsmate for fremstilling av eprosartan |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US6172237B1 (ja) |
| EP (1) | EP0970073B1 (ja) |
| JP (1) | JP4537499B2 (ja) |
| KR (1) | KR100573638B1 (ja) |
| CN (1) | CN1085208C (ja) |
| AP (1) | AP1128A (ja) |
| AR (1) | AR011125A1 (ja) |
| AT (1) | ATE280765T1 (ja) |
| AU (1) | AU730383B2 (ja) |
| BG (1) | BG63804B1 (ja) |
| BR (1) | BR9808664A (ja) |
| CA (1) | CA2281708C (ja) |
| CO (1) | CO4950550A1 (ja) |
| CY (1) | CY2555B1 (ja) |
| CZ (1) | CZ296349B6 (ja) |
| DE (1) | DE69827240T2 (ja) |
| DK (1) | DK0970073T3 (ja) |
| EA (1) | EA001659B1 (ja) |
| EG (1) | EG23935A (ja) |
| ES (1) | ES2231963T3 (ja) |
| HU (1) | HU228781B1 (ja) |
| ID (1) | ID23181A (ja) |
| IL (1) | IL131309A (ja) |
| IN (2) | IN187999B (ja) |
| MA (1) | MA24470A1 (ja) |
| MY (1) | MY118704A (ja) |
| NO (1) | NO317194B1 (ja) |
| NZ (1) | NZ337180A (ja) |
| OA (1) | OA11146A (ja) |
| PE (1) | PE59299A1 (ja) |
| PL (1) | PL192838B1 (ja) |
| PT (1) | PT970073E (ja) |
| RO (1) | RO119719B1 (ja) |
| SA (1) | SA98190082B1 (ja) |
| SI (1) | SI0970073T1 (ja) |
| SK (1) | SK285036B6 (ja) |
| TR (1) | TR199901936T2 (ja) |
| TW (1) | TW399050B (ja) |
| UA (1) | UA54487C2 (ja) |
| WO (1) | WO1998035963A1 (ja) |
| ZA (1) | ZA981207B (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137613A1 (en) * | 2006-12-27 | 2010-06-03 | Hetero Drugs Limited | Process for eprosartan |
| EP2181109A4 (en) * | 2007-07-25 | 2011-08-03 | Hetero Drugs Ltd | CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN |
| EP2295431A3 (en) * | 2007-07-25 | 2011-08-03 | Hetero Drugs Limited | Substantially pure eprosartan free base |
| WO2009084028A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd | Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate |
| CN101215284B (zh) * | 2007-12-31 | 2010-10-13 | 浙江华海药业股份有限公司 | 一种改进的依普罗沙坦的制备方法 |
| US20110054186A1 (en) * | 2008-03-31 | 2011-03-03 | Hetero Research Foundation | Process for eprosartan intermediate |
| WO2010023688A2 (en) * | 2008-08-25 | 2010-03-04 | Matrix Laboratories Limited | An improved process for the preparation of eprosartan |
| WO2011004384A2 (en) | 2009-06-05 | 2011-01-13 | Glochem Industries Limited | Process for the preparation of eprosartan |
| WO2011051975A1 (en) | 2009-10-30 | 2011-05-05 | Matrix Laboratories Ltd | An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| NZ239161A (en) * | 1990-07-31 | 1994-01-26 | Smithkline Beecham Corp | Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments, |
| AU9137791A (en) * | 1990-12-14 | 1992-07-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| US5395847A (en) * | 1993-12-02 | 1995-03-07 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| EP0850225B1 (en) * | 1994-05-20 | 2003-08-13 | Smithkline Beecham Corporation | Intermediate for preparing a pharmaceutically active compound |
-
1998
- 1998-02-10 AR ARP980100585A patent/AR011125A1/es active IP Right Grant
- 1998-02-11 EG EG15598A patent/EG23935A/xx active
- 1998-02-12 IN IN360DE1998 patent/IN187999B/en unknown
- 1998-02-12 MA MA24961A patent/MA24470A1/fr unknown
- 1998-02-12 MY MYPI98000577A patent/MY118704A/en unknown
- 1998-02-12 PE PE1998000101A patent/PE59299A1/es not_active Application Discontinuation
- 1998-02-13 UA UA99084635A patent/UA54487C2/uk unknown
- 1998-02-13 CO CO98007700A patent/CO4950550A1/es unknown
- 1998-02-13 AU AU61508/98A patent/AU730383B2/en not_active Ceased
- 1998-02-13 US US09/355,185 patent/US6172237B1/en not_active Expired - Lifetime
- 1998-02-13 NZ NZ337180A patent/NZ337180A/xx unknown
- 1998-02-13 KR KR1019997007273A patent/KR100573638B1/ko not_active IP Right Cessation
- 1998-02-13 DK DK98906229T patent/DK0970073T3/da active
- 1998-02-13 CZ CZ0285299A patent/CZ296349B6/cs not_active IP Right Cessation
- 1998-02-13 PL PL335075A patent/PL192838B1/pl unknown
- 1998-02-13 EP EP98906229A patent/EP0970073B1/en not_active Expired - Lifetime
- 1998-02-13 PT PT98906229T patent/PT970073E/pt unknown
- 1998-02-13 RO RO99-00885A patent/RO119719B1/ro unknown
- 1998-02-13 DE DE69827240T patent/DE69827240T2/de not_active Expired - Lifetime
- 1998-02-13 ID IDW990839A patent/ID23181A/id unknown
- 1998-02-13 EA EA199900740A patent/EA001659B1/ru not_active IP Right Cessation
- 1998-02-13 AP APAP/P/1999/001620A patent/AP1128A/en active
- 1998-02-13 HU HU0001994A patent/HU228781B1/hu not_active IP Right Cessation
- 1998-02-13 AT AT98906229T patent/ATE280765T1/de active
- 1998-02-13 SK SK1087-99A patent/SK285036B6/sk not_active IP Right Cessation
- 1998-02-13 ES ES98906229T patent/ES2231963T3/es not_active Expired - Lifetime
- 1998-02-13 JP JP52813798A patent/JP4537499B2/ja not_active Expired - Fee Related
- 1998-02-13 BR BR9808664-2A patent/BR9808664A/pt not_active IP Right Cessation
- 1998-02-13 SI SI9830722T patent/SI0970073T1/xx unknown
- 1998-02-13 CN CN98802484A patent/CN1085208C/zh not_active Expired - Fee Related
- 1998-02-13 CA CA002281708A patent/CA2281708C/en not_active Expired - Fee Related
- 1998-02-13 TR TR1999/01936T patent/TR199901936T2/xx unknown
- 1998-02-13 IL IL13130998A patent/IL131309A/en not_active IP Right Cessation
- 1998-02-13 WO PCT/US1998/002412 patent/WO1998035963A1/en active IP Right Grant
- 1998-02-13 ZA ZA981207A patent/ZA981207B/xx unknown
- 1998-04-15 TW TW087101969A patent/TW399050B/zh not_active IP Right Cessation
- 1998-05-24 SA SA98190082A patent/SA98190082B1/ar unknown
-
1999
- 1999-08-10 BG BG103650A patent/BG63804B1/bg unknown
- 1999-08-13 NO NO19993913A patent/NO317194B1/no not_active IP Right Cessation
- 1999-08-13 OA OA9900179A patent/OA11146A/en unknown
-
2002
- 2002-01-28 IN IN58DE2002 patent/IN192743B/en unknown
-
2006
- 2006-04-07 CY CY0600011A patent/CY2555B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO177265B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazoler | |
| KR20120055586A (ko) | 약학적 활성 화합물의 제조 방법 | |
| NO317194B1 (no) | Fremgangsmate for fremstilling av eprosartan | |
| KR102018929B1 (ko) | (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법 | |
| CA3105786A1 (en) | (r)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as ep4 receptor antagonist | |
| US6458963B1 (en) | Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates | |
| CN110143945B (zh) | 一种4-取代基甲基-1-(2h)酞嗪酮的简便制备方法 | |
| JPS59118784A (ja) | 置換イミダゾ〔１，５−ａ〕ピリジン及びその製造方法，並びに該化合物を含有する医薬 | |
| SK66793A3 (en) | Imidazolyl substituted derivatives of phenylpropane and cinnamon acid | |
| MXPA99007533A (en) | Process for preparing eprosartan | |
| NO309084B1 (no) | FremgangsmÕte for fremstilling av 5-okso-3-fenyl-3- cykloheksenkarboksylsyre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |